(MedPage Today) — More than a third of older men with lower urinary tract symptoms (LUTS) derived little or no benefit from an alpha-blocker and might be candidates for “deprescribing,” a small, randomized study suggested. During active treatment…
Many Men With LUTS Could Be Candidates to Stop Alpha-Blocker Treatment Read Post »
CorePlus Integrates Prostate Cancer Risk Stratification Tool into Digital Pathology Diagnostic Workflow Imaging Technology News
New drug against metastatic prostate cancer made entirely from human proteins Medical Xpress
Nebraska Hematology Oncology becomes state’s only trial site for new prostate cancer treatment KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE
(MedPage Today) — The bacillus Calmette-Guérin (BCG) vaccine, commonly used against tuberculosis, changed how immune cells behaved and altered markers linked to Alzheimer’s disease in a pilot study involving two open-label trials. In a year…
Alzheimer’s Biomarkers Change After Tuberculosis Vaccination Read Post »
(MedPage Today) — Note that some links may require registration or subscription. A North Carolina man who claims his 0.38-inch penis is the world’s smallest started a fundraiser for enlargement surgery. (The Guardian) Michigan parents are facing…
‘Tiniest Penis’ Fundraiser; Flu Vaccine Maker Investigated; FDA Rejects Gout Drug Read Post »
(MedPage Today) — A multicomponent blood-based biomarker test that combines prostate-specific antigen (PSA) with additional plasma protein biomarkers, a polygenic risk score, and clinical variables identified more clinically significant prostate…
Multicomponent Test Tops PSA for Clinically Significant Prostate Cancers Read Post »
(MedPage Today) — The FDA approved oral tebipenem pivoxil (Utebzi) as the first oral carbapenem antibiotic to treat complicated urinary tract infections (UTIs), the agency announced on Wednesday. Tebipenem pivoxil is indicated for complicated…
First Oral Carbapenem Approved for Complicated UTIs Read Post »
(MedPage Today) — The FDA approved capivasertib (Truqap) in combination with abiraterone (Zytiga) and prednisone for PTEN-deficient prostate cancer, the agency announced on Friday. Approval stipulates use in metastatic hormone-sensitive prostate…
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting Read Post »
(MedPage Today) — CHICAGO — A paradigm-changing clinical trial in prostate cancer showed that perioperative apalutamide (Erleada) and androgen deprivation therapy (ADT) significantly reduced the risk of metastasis in high-risk localized disease…
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy Read Post »